The DOI matches its Crossref record; 158 of the 158 references it cites were found in a registry or an index.
Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy
Abstract
The bisphosphonates (BPs) are well established as the treatments of choice for disorders of excessive bone resorption, including Paget's disease of bone, myeloma and bone metastases, and osteoporosis. There is considerable new knowledge about how BPs work. Their classical pharmacological effects appear to result from two key properties: their affinity for bone mineral and their inhibitory effects on osteoclasts. Mineral binding affinities differ among the clinically used BPs and may influence their differential distribution within bone, their biological potency, and their duration of action. The inhibitory effects of the nitrogen‐containing BPs (including alendronate, risedronate, ibandronate, and zoledronate) on osteoclasts appear to result from their inhibition of farnesyl pyrophosphate synthase (FPPS), a key branch‐point enzyme in the mevalonate pathway. FPPS generates isoprenoid lipids used for the posttranslational modification of small GTP‐binding proteins essential for osteoclast function. Effects on other cellular pathways, such as preventing apoptosis in osteocytes, are emerging as other potentially important mechanisms of action. As a class, BPs share several common properties. However, as with other classes of drugs, there are obvious chemical, biochemical, and pharmacological differences among the various individual BPs. Each BP has a unique profile that may help to explain potential important clinical differences among the BPs, in terms of speed of onset of fracture reduction, antifracture efficacy at different skeletal sites, and the degree and duration of suppression of bone turnover. As we approach the 40th anniversary of the discovery of their biological effects, there remain further opportunities for using their properties for medical purposes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Khosla, S., Burr, D., Cauley, J., Dempster, D. W., Ebeling, P. R., Felsenberg, D., Gagel, R. F., Gilsanz, V., Guise, T., Koka, S., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0707onj · Cited by 1,650
Self-citationSeverely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maalouf, N., Gottschalk, F. A., & Pak, C. Y. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0952 · Cited by 1,432
Black, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Self-citationBlack, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., Garnero, P., Bouxsein, M. L., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,174
Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Storm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sorensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 935
Bisphosphonates: A review of their pharmacokinetic properties
Lin, J. H. (1996) · Bone · doi:10.1016/8756-3282(95)00445-9 · Cited by 932
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890
Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J.-M., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 877
Nancollas, G. H., Tang, R., Phipps, R. J., Henneman, Z., Gulde, S., Wu, W., Mangood, A., Russell, R. G. G., & Ebetino, F. H. (2006) · Bone · doi:10.1016/j.bone.2005.05.003 · Cited by 862
Self-citationFleisch, H., Graham, R., Russell, G., & Francis, M. D. (1969) · Science · doi:10.1126/science.165.3899.1262 · Cited by 758
Osteonecrosis of the Jaw and Bisphosphonates
(2005) · New England Journal of Medicine · doi:10.1056/nejm200507073530120 · Cited by 744
Garnero, P. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.79.6.1693 · Cited by 707
Fisher, J. E., Rogers, M. J., Halasy, J. M., Luckman, S. P., Hughes, D. E., Masarachia, P. J., Wesolowski, G., Russell, R. G. G., Rodan, G. A., & Reszka, A. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.133 · Cited by 676
Self-citationRole of the Mouse ank Gene in Control of Tissue Calcification and Arthritis
Ho, A. M., Johnson, M. D., & Kingsley, D. M. (2000) · Science · doi:10.1126/science.289.5477.265 · Cited by 652
Francis, M. D., Graham, R., Russell, G., & Fleisch, H. (1969) · Science · doi:10.1126/science.165.3899.1264 · Cited by 608
Pols, H. A. P., Felsenberg, D., Hanley, D. A., Štepán, J., Muñoz-Torres, M., Wilkin, T. J., Qin-sheng, G., Galich, A. M., Vandormael, K., Yates, A. J., et al. (1999) · Osteoporosis International · doi:10.1007/pl00004171 · Cited by 593
New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Rogers, M. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033453640 · Cited by 579
Self-citationThe molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs
Kavanagh, K. L., Guo, K., Dunford, J. E., Wu, X., Knapp, S., Ebetino, F. H., Rogers, M. J., Russell, R. G. G., & Oppermann, U. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601643103 · Cited by 536
Self-citationChavassieux, P. M., Arlot, M. E., Reda, C., Wei, L., Yates, A. J., & Meunier, P. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119668 · Cited by 523
Effect of Pyrophosphate on Hydroxyapatite and Its Implications in Calcium Homeostasis
FLEISCH, H., RUSSELL, R. G. G., & STRAUMANN, F. (1966) · Nature · doi:10.1038/212901a0 · Cited by 517
Self-citationFarnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing Bisphosphonates
van Beek, E., Pieterman, E., Cohen, L., Löwik, C., & Papapoulos, S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1499 · Cited by 496
Aguirre, J. I., Plotkin, L. I., Stewart, S. A., Weinstein, R. S., Parfitt, A. M., Manolagas, S. C., & Bellido, T. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060107 · Cited by 494
Inorganic pyrophosphate generation and disposition in pathophysiology
Terkeltaub, R. A. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.281.1.c1 · Cited by 484
Bisphosphonates in Bone Disease: From the Laboratory to the Patient
Fleisch, H. A. (1995) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 472
A systematic review of the role of bisphosphonates in metastatic disease
Ross, J., Saunders, Y., Edmonds, P., Patel, S., Wonderling, D., Normand, C., & Broadley, K. (2004) · Health Technology Assessment · doi:10.3310/hta8040 · Cited by 467
Bisphosphonate-Induced Osteopetrosis
Whyte, M. P., Wenkert, D., Clements, K. L., McAlister, W. H., & Mumm, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023110 · Cited by 446
Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's Disease
Reid, I. R., Miller, P., Lyles, K., Fraser, W., Brown, J. P., Saidi, Y., Mesenbrink, P., Su, G., Pak, J., Zelenakas, K., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044241 · Cited by 439
Frith, J. C., Mönkkönen, J., Blackburn, G. M., Russell, R. G. G., & Rogers, M. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.9.1358 · Cited by 437
Self-citationOsteocytes as Dynamic Multifunctional Cells
BONEWALD, L. F. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.018 · Cited by 417
Bisphosphonates: From Bench to Bedside
RUSSELL, R. G. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.041 · Cited by 410
Self-citationRegulation of Osteoclast Function
Suda, T., Nakamura, I., Jimi, E., & Takahashi, N. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.6.869 · Cited by 408
Fedde, K. N., Blair, L., Silverstein, J., Coburn, S. P., Ryan, L. M., Weinstein, R. S., Waymire, K., Narisawa, S., Millán, J. L., Macgregor, G. R., et al. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.12.2015 · Cited by 405
Bisphosphonates: Preclinical Review
Green, J. R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90004-3 · Cited by 405
Alendronate Is a Specific, Nanomolar Inhibitor of Farnesyl Diphosphate Synthase
Bergstrom, J. D., Bostedor, R. G., Masarachia, P. J., Reszka, A. A., & Rodan, G. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1502 · Cited by 402
Relation between age, femoral neck cortical stability, and hip fracture risk
Mayhew, P. M., Thomas, C. D., Clement, J. G., Loveridge, N., Beck, T. J., Bonfield, W., Burgoyne, C. J., & Reeve, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66870-5 · Cited by 397
Balena, R., Toolan, B. C., Shea, M., Markatos, A., Myers, E. R., Lee, S. C., Opas, E. E., Seedor, J. G., Klein, H., & Frankenfield, D. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116872 · Cited by 396
The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals
Jung, A., Bisaz, S., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547227 · Cited by 381
Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases
Chen, T., Berenson, J., Vescio, R., Swift, R., Gilchick, A., Goodin, S., LoRusso, P., Ma, P., Ravera, C., Deckert, F., et al. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002762491316 · Cited by 374
Dr. Coxon, F. P., Helfrich, M. H., Van't Hof, R., Sebti, S., Ralston, S. H., Hamilton, A., & Rogers, M. J. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1467 · Cited by 361
Self-citationHughes, D. E., MacDonald, B. R., Russell, R. G., & Gowen, M. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114100 · Cited by 357
Self-citationRosen, C. J., Hochberg, M. C., Bonnick, S. L., McClung, M., Miller, P., Broy, S., Kagan, R., Chen, E., Petruschke, R. A., Thompson, D. E., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040920 · Cited by 345
Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp, P. M., van der Wee-Pals, L. J. A., LENNEP, M. V., Cw, T., & Bijvoet, O. L. (1986) · PubMed · Cited by 345
Recker, R., Lappe, J., Davies, K. M., & Heaney, R. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040710 · Cited by 343
Russell, R. G. G., Mühlbauer, R. C., Bisaz, S., Williams, D. A., & Fleisch, H. (1970) · Calcified Tissue Research · doi:10.1007/bf02196199 · Cited by 341
Self-citationLehenkari, P. P., Kellinsalmi, M., Näpänkangas, J. P., Ylitalo, K. V., Mönkkönen, J., Rogers, M. J., Azhayev, A., Väänänen, H. K., & Hassinen, I. E. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12222-5 · Cited by 333
Self-citationLai, K.-A. (2005) · The Journal of Bone and Joint Surgery (American) · doi:10.2106/jbjs.d.02959 · Cited by 332
Fleisch, H. A., Russell, R. G. G., Bisaz, S., Mühlbauer, R. C., & Williams, D. A. (1970) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1970.tb00591.x · Cited by 325
Self-citationWeinstein, R. S., Chen, J.-R., Powers, C. C., Stewart, S. A., Landes, R. D., Bellido, T., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214538 · Cited by 313
Delmas, P. D., & Seeman, E. (2004) · Bone · doi:10.1016/j.bone.2003.12.022 · Cited by 294
Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis
Khan, S. A., Kanis, J. A., Vasikaran, S., Kline, W. F., Matuszewski, B. K., McCloskey, E. V., Beneton, M. N. C., Gertz, B. J., Sciberras, D. G., Holland, S. D., et al. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.10.1700 · Cited by 293
Mönkkönen, H., Auriola, S., Lehenkari, P., Kellinsalmi, M., Hassinen, I. E., Vepsäläinen, J., & Mönkkönen, J. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706628 · Cited by 280
Luckman, S. P., Coxon, F. P., Ebetino, F. H., Russell, R. G. G., & Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.11.1668 · Cited by 272
Self-citationStructural Basis for Bisphosphonate-mediated Inhibition of Isoprenoid Biosynthesis
Hosfield, D. J., Zhang, Y., Dougan, D. R., Broun, A., Tari, L. W., Swanson, R. V., & Finn, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300511200 · Cited by 272
Bisphosphonate Osteochemonecrosis (Bis-Phossy Jaw): Is This Phossy Jaw of the 21st Century?
Hellstein, J. W., & Marek, C. L. (2005) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2005.01.010 · Cited by 270
Frith, J. C., M�nkk�nen, J., Auriola, S., M�nkk�nen, H., & Rogers, M. J. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200109)44:9<2201::aid-art374>3.0.co;2-e · Cited by 268
Self-citationEffects of bisphosphonates on isolated Rat osteoclasts as examined by reflected light microscopy
Sato, M., & Grasser, W. (1990) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650050107 · Cited by 264
Recent advances in understanding the mechanism of action of bisphosphonates
COXON, F., THOMPSON, K., & ROGERS, M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.03.005 · Cited by 252
Self-citationComparison of the distribution of 3H-alendronate and 3H-Etidronate in rat and mouse bones
Masarachia, P., Weinreb, M., Balena, R., & Rodan, G. A. (1996) · Bone · doi:10.1016/8756-3282(96)00182-2 · Cited by 248
Nürnberg, P., Thiele, H., Chandler, D., Höhne, W. E., Cunningham, M. L., Ritter, H., Leschik, G., Uhlmann, K., Mischung, C., Harrop, K., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-37 · Cited by 246
Thompson, K., Rogers, M. J., Coxon, F. P., & Crockett, J. C. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.020776 · Cited by 242
Self-citationLong-Term Safety of Bisphosphonates
Ott, S. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0057 · Cited by 241
Russell, R. G. G., Bisaz, S., Donath, A., Morgan, D. B., & Fleisch, H. (1971) · Journal of Clinical Investigation · doi:10.1172/jci106589 · Cited by 240
Self-citationPlotkin, L. I., Aguirre, J. I., Kousteni, S., Manolagas, S. C., & Bellido, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412817200 · Cited by 240
Van Beek, E., Löwik, C., Van Der Pluijm, G., & Papapoulos, S. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.5.722 · Cited by 237
Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro
Benford, H. L., McGowan, N. W. A., Helfrich, M. H., Nuttall, M. E., & Rogers, M. J. (2001) · Bone · doi:10.1016/s8756-3282(01)00412-4 · Cited by 235
Self-citationWatts, N. B., Cooper, C., Lindsay, R., Eastell, R., Manhart, M. D., Barton, I. P., van Staa, T.-P., & Adachi, J. D. (2004) · Journal of Clinical Densitometry · doi:10.1385/jcd:7:3:255 · Cited by 229
Self-citationInamasu, J., Guiot, B. H., & Sachs, D. C. (2006) · Neurosurgery · doi:10.1227/01.neu.0000215867.87770.73 · Cited by 229
Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs
Rondeau, J., Bitsch, F., Bourgier, E., Geiser, M., Hemmig, R., Kroemer, M., Lehmann, S., Ramage, P., Rieffel, S., Strauss, A., et al. (2006) · ChemMedChem · doi:10.1002/cmdc.200500059 · Cited by 226
Harrington, J. T., Ste-Marie, L. G., Brandi, M. L., Civitelli, R., Fardellone, P., Grauer, A., Barton, I., & Boonen, S. (2004) · Calcified Tissue International · doi:10.1007/s00223-003-0042-4 · Cited by 223
Mutations in ANKH Cause Chondrocalcinosis
Pendleton, A., Johnson, M. D., Hughes, A., Gurley, K. A., Ho, A. M., Doherty, M., Dixey, J., Gillet, P., Loeuille, D., McGrath, R., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/343054 · Cited by 223
Statins Prevent Bisphosphonate-Induced γ,δ-T-Cell Proliferation and Activation In Vitro
Thompson, K., & Rogers, M. J. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301230 · Cited by 217
Self-citationEriksen, E. F., Melsen, F., Sod, E., Barton, I., & Chines, A. (2002) · Bone · doi:10.1016/s8756-3282(02)00869-4 · Cited by 211
DIPHOSPHONATES AND PAGET'S DISEASE OF BONE
SMITH (1971) · The Lancet · doi:10.1016/s0140-6736(71)91447-4 · Cited by 203
McCloskey, E. V., Beneton, M., Charlesworth, D., Kayan, K., de Takats, D., Dey, A., Orgee, J., Ashford, R., Forster, M., Cliffe, J., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061008 · Cited by 200
Reichenberger, E., Tiziani, V., Watanabe, S., Park, L., Ueki, Y., Santanna, C., Baur, S. T., Shiang, R., Grange, D. K., Beighton, P., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/320612 · Cited by 199
Parfitt, A. M. (1976) · Metabolism · doi:10.1016/0026-0495(76)90151-7 · Cited by 196
The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease.
Fogelman, I., Bessent, R. G., Turner, J. G., Citrin, D. L., Boyle, I. T., & Greig, W. R. (1978) · PubMed · Cited by 192
Dr. Löwik, C. W. G. M., Van Der Pluijm, G., Van Der Wee-Pals, L. J. A., Van Treslong-De Groot, H. B., & Bijvoet, O. L. M. (1988) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650030210 · Cited by 191
Fleisch, H., Russell, R. G. G., Bisaz, S., Casey, P. A., & Mühlbauer, R. C. (1968) · Calcified Tissue Research · doi:10.1007/bf02065192 · Cited by 190
Self-citationDunford, J. E., Rogers, M. J., Ebetino, F. H., Phipps, R. J., & Coxon, F. P. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060118 · Cited by 189
Self-citationDifferentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates
van Beek, E. R., Cohen, L. H., Leroy, I. M., Ebetino, F. H., Löwik, C. W. G. M., & Papapoulos, S. E. (2003) · Bone · doi:10.1016/j.bone.2003.07.007 · Cited by 184
Self-citationEfficacy of risedronate on clinical vertebral fractures within six months
Roux, C., Seeman, E., Eastell, R., Adachi, J., Jackson, R. D., Felsenberg, D., Songcharoen, S., Rizzoli, R., Munno, O. D., Horlait, S., et al. (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125003125 · Cited by 184
Self-citationDIPHOSPHONATES IN THE TREATMENT OF MYOSITIS OSSIFICANS
Bassett, C. A. L., Donath, A., Macagno, F., Preisig, R., Fleisch, H. A., & Francis, M. D. (1969) · The Lancet · doi:10.1016/s0140-6736(69)92293-4 · Cited by 182
Sirohi, B., & Powles, R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15736-x · Cited by 181
Price, P. A., Thomas, G. R., Pardini, A. W., Figueira, W. F., Caputo, J. M., & Williamson, M. K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106366200 · Cited by 179
EXCRETION OF INORGANIC PYROPHOSPHATE IN HYPOPHOSPHATASIA
RUSSELL, R. (1965) · The Lancet · doi:10.1016/s0140-6736(65)91422-4 · Cited by 178
Self-citationMcClung, M., Recker, R., Miller, P., Fiske, D., Minkoff, J., Kriegman, A., Zhou, W., Adera, M., & Davis, J. (2007) · Bone · doi:10.1016/j.bone.2007.03.011 · Cited by 176
Silverman, S. L., Watts, N. B., Delmas, P. D., Lange, J. L., & Lindsay, R. (2007) · Osteoporosis International · doi:10.1007/s00198-006-0274-z · Cited by 174
Self-citationKavanagh, K. L., Dunford, J. E., Bunkòczi, G., Russell, R. G. G., & Oppermann, U. C. T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602603200 · Cited by 166
Self-citationRogers, M. J. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0024-1 · Cited by 164
Self-citationWatts, N. B., Geusens, P., Barton, I. P., & Felsenberg, D. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050814 · Cited by 164
Self-citationPlotkin, L. I., Manolagas, S. C., & Bellido, T. (2006) · Bone · doi:10.1016/j.bone.2006.02.060 · Cited by 162
Reitsma, P. H., Bijvoet, O. L. M., Verlinden-Ooms, H., & van der Wee-Pals, L. J. A. (1980) · Calcified Tissue International · doi:10.1007/bf02408534 · Cited by 161
Bisphosphonates in breast cancer
Coleman, R. E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi162 · Cited by 158
Azuma, Y., Sato, H., Oue, Y., OKABE, K., Ohta, T., Tsuchimoto, M., & Kiyoki, M. (1995) · Bone · doi:10.1016/8756-3282(94)00035-x · Cited by 157
Boonen, S., Laan, R., Barton, I. P., & Watts, N. B. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1945-x · Cited by 155
Self-citationLeu, C., Luegmayr, E., Freedman, L. P., Rodan, G. A., & Reszka, A. A. (2005) · Bone · doi:10.1016/j.bone.2005.07.023 · Cited by 154
Mashiba, T., Mori, S., Komatsubara, S., Cao, Y., Manabe, T., Norimatsu, H., & Burr, D. B. (2005) · Journal of Bone and Mineral Metabolism · doi:10.1007/bf03026321 · Cited by 153
Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing
Bauss, F., & Russell, R. G. G. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1612-7 · Cited by 148
Self-citationBonnick, S. L., Saag, K. G., Kiel, D. P., McClung, M. R., Hochberg, M. C., Burnett‐Bowie, S. M., Sebba, A. I., Kagan, R., Chen, E., Thompson, D. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2602 · Cited by 145
Antiresorptive dose-response relationships across three generations of bisphosphonates.
Sietsema, W. K., Ebetino, F. H., Salvagno, A. M., & Bevan, J. A. (1989) · PubMed · Cited by 139
Self-citationEffects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men
Finkelstein, J. S., Leder, B. Z., Burnett‐Bowie, S. M., Wyland, J. J., Lee, H., de la Paz, A. V., Gibson, K. L., & Neer, R. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0190 · Cited by 138
Little, D. G., McDonald, M. M., Bransford, R., Godfrey, C., & Amanat, N. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050712 · Cited by 137
Anderson, H. C., Harmey, D., Pleshko, N. L., Garimella, R., Sipe, J. B., Tague, S. E., Bi, X., Johnson, K., Terkeltaub, R. A., & Millán, J. L. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62481-9 · Cited by 136
Gabelli, S. B., McLellan, J. S., Montalvetti, A., et al. (2005) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20754 · Cited by 133
Little, D. G., Peat, R. A., McEvoy, A., Williams, P. R., Smith, E. J., & Baldock, P. A. J. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.11.2016 · Cited by 131
Genetic studies of disorders of calcium crystal deposition
Timms, A. E. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.7.725 · Cited by 131
Borah, B., Ritman, E. L., Dufresne, T. E., Jorgensen, S. M., Liu, S., Sacha, J. P., Phipps, R. J., & Turner, R. T. (2005) · Bone · doi:10.1016/j.bone.2005.03.017 · Cited by 130
Self-citationDurchschlag, E., Paschalis, E. P., Zoehrer, R., Roschger, P., Fratzl, P., Recker, R. R., Phipps, R. J., & Klaushofer, K. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060701 · Cited by 129
Self-citationvan Beek, E. R., Löwik, C. W. G. M., Ebetino, F. H., & Papapoulos, S. E. (1998) · Bone · doi:10.1016/s8756-3282(98)00120-3 · Cited by 125
Self-citationBisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?
WYNGAERT, T. V. D., Huizing, M. T., & Vermorken, J. B. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl294 · Cited by 125
Biochemical and Genetic Analysis of ANK in Arthritis and Bone Disease
Gurley, K. A., Reimer, R. J., & Kingsley, D. M. (2006) · The American Journal of Human Genetics · doi:10.1086/509881 · Cited by 123
Fleisch, H. A., Maerki, J., & Russell, R. G. G. (1966) · Experimental Biology and Medicine · doi:10.3181/00379727-122-31123 · Cited by 121
Self-citationWilliams, C. J., Zhang, Y., Timms, A. E., Bonavita, G., Caeiro, F., Broxholme, J., Cuthbertson, J. M., Jones, E. Y., Marchegiani, R., Reginato, A. J., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/343053 · Cited by 117
Self-citationFas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis
Kogianni, G., Mann, V., Ebetino, F. H., NUTTALL, M. E., Nijweide, P. J., Simpson, H., & Noble, B. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.04.048 · Cited by 117
Self-citationRuf, N., Uhlenberg, B., Terkeltaub, R. A., et al. (2004) · Human Mutation · doi:10.1002/humu.9297 · Cited by 114
Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women
Bone, H. G. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.1.265 · Cited by 114
Recker, R. R., Weinstein, R. S., Chesnut, C. H., Schimmer, R. C., Mahoney, P., Hughes, C., Bonvoisin, B., & Meunier, P. J. (2004) · Osteoporosis International · doi:10.1007/s00198-003-1530-0 · Cited by 113
Wronski, T. J., Yen, C. ‐., & Scott, K. S. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650060410 · Cited by 106
Little, D. G., Smith, N. C., Williams, P. R., BRIODY, J. N., Bilston, L. E., Smith, E. J., Gardiner, E. M., & Cowell, C. T. C. T. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.7.1300 · Cited by 105
Rogers, M. J., Ji, X., Russell, R. G. G., Blackburn, G. M., Williamson, M. P., Bayless, A. V., Ebetino, F. H., & Watts, D. J. (1994) · Biochemical Journal · doi:10.1042/bj3030303 · Cited by 102
Self-citationPharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption
Green, J. R., & Rogers, M. J. (2002) · Drug Development Research · doi:10.1002/ddr.10071 · Cited by 100
Self-citationThe bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats
Kurth, A. H. A., Eberhardt, C., Müller, S., Steinacker, M., Schwarz, M., & Bauss, F. (2005) · Bone · doi:10.1016/j.bone.2004.12.017 · Cited by 99
The long-term skeletal effects of EHDP in dogs
Flora, L., Hassing, G. S., Cloyd, G. G., Bevan, J. A., PARFITT, A. M., & Villanueva, A. R. (1981) · Metabolic Bone Disease and Related Research · doi:10.1016/0221-8747(81)90045-x · Cited by 95
Ueber die Einwirkung des Chloracetyls auf phosphorige Säure
Menschutkin, N. (1865) · Justus Liebig s Annalen der Chemie · doi:10.1002/jlac.18651330307 · Cited by 95
Szabo, C. M., Matsumura, Y., Fukura, S., Martin, M., Sanders, J. M., Sengupta, S., Cieslak, J. A., Loftus, T. C., Lea, C. R., Lee, H.-J., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010412y · Cited by 94
van Beek, E. R., Löwik, C. W. G. M., Que, I., & Papapoulos, S. E. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111016 · Cited by 94
Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading
Follet, H., Li, J., Phipps, R. J., Hui, S. L., Condon, K. W., & Burr, D. B. (2006) · Bone · doi:10.1016/j.bone.2006.12.052 · Cited by 90
Self-citationBisphosphonate actions: Physical chemistry revisited
Papapoulos, S. E. (2006) · Bone · doi:10.1016/j.bone.2006.01.141 · Cited by 89
Mao, J., Mukherjee, S., Zhang, Y., Cao, R., Sanders, J. M., Song, Y., Zhang, Y., Meints, G. A., Gao, Y. G., Mukkamala, D., et al. (2006) · Journal of the American Chemical Society · doi:10.1021/ja061737c · Cited by 89
Bauss, F., Lalla, S., Endele, R., & Hothorn, L. A. (2002) · PubMed · Cited by 86
Zoledronic acid improves femoral head sphericity in a rat model of perthes disease
Little, D. G., McDonald, M. M., Sharpe, I. T., et al. (2005) · Journal of Orthopaedic Research® · doi:10.1016/j.orthres.2004.11.015 · Cited by 83
Osteonecrosis of the jaw related to the use of bisphosphonates
WYNGAERT, T. V. D., Huizing, M. T., & Vermorken, J. B. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32819f820b · Cited by 79
Risedronate Reduces the Risk of First Vertebral Fracture in Osteoporotic Women
Heaney, R. P., Zizic, T. M., Fogelman, I., Olszynski, W. P., Geusens, P., Kasibhatla, C., Alsayed, N., Isaia, G., Davie, M. W. J., & Chesnut, C. H. (2002) · Osteoporosis International · doi:10.1007/s001980200061 · Cited by 78
Mitchell, D. Y., Barr, W. H., Eusebio, R. A., Pallone, K. A., Duke, F. P., Russell, D. A., Nesbitt, J. D., Powell, J. H., & Thompson, G. A. (2001) · Pharmaceutical Research · doi:10.1023/a:1011024200280 · Cited by 78
Eastell, R., Hannon, R. A., Garnero, P., Campbell, M. J., & Delmas, P. D. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.07090b · Cited by 76
Trechsel, U., Stutzer, A., & Fleisch, H. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113257 · Cited by 74
Is There a Role for Bisphosphonates in Chronic Kidney Disease?
Miller, P. D. (2007) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2007.00271.x · Cited by 73
Wilkinson, J. M., Eagleton, A. C., Stockley, I., Peel, N. F. A., Hamer, A. J., & Eastell, R. (2004) · Journal of Orthopaedic Research® · doi:10.1016/j.orthres.2004.06.004 · Cited by 73
Cremers, S., Sparidans, R. W., den Hartigh, J., Hamdy, N. A. T., Vermeij, P., & Papapoulos, S. E. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0411-8 · Cited by 71
Miller, P. D. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-005-0018-6 · Cited by 70
PTH and interactions with bisphosphonates.
Ja, G., Kneissel, M., Js, T., & Mosekilde, L. (2000) · PubMed · Cited by 67
Bisphosphonates as Inhibitors of Trypanosoma cruzi Hexokinase
Sanz-Rodríguez, C. E., Concepción, J. L., Pékerar, S., Oldfield, E., & Urbina, J. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607286200 · Cited by 63
Power, J., Noble, B., Loveridge, N., Bell, K. L., Rushton, N., & REEVE, J. (2001) · Calcified Tissue International · doi:10.1007/s00223-001-0013-6 · Cited by 57
Liberman, U. A., Hochberg, M. C., Geusens, P., SHAH, A., Lin, J. T., Chattopadhyay, A., & Ross, P. D. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01148.x · Cited by 53
Bauss, F., Schenk, R., Hört, S., Müller‐Beckmann, B., & Sponer, G. (2004) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2003.11.003 · Cited by 46
Lipton, A. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.s.002 · Cited by 33
The use of cyclical etidronate in osteoporosis: changes after completion of 3 years treatment
Fairney, A., Kyd, P., Thomas, E., & Wilson, J. (1998) · Lara D. Veeken · doi:10.1093/rheumatology/37.1.51 · Cited by 15
Cited by
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
Self-citationRemarkable Potential of the α-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry
Mucha, A., Kafarski, P., & Berlicki, Ł. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200587f · Cited by 672
The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data
Allen, M. R., & Burr, D. B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.007 · Cited by 451
The relationship between the chemistry and biological activity of the bisphosphonates
Ebetino, F. H., Hogan, A.-M. L., Sun, S., Tsoumpra, M. K., Duan, X., Triffitt, J. T., Kwaasi, A. A., Dunford, J. E., Barnett, B. L., Oppermann, U., et al. (2011) · Bone · doi:10.1016/j.bone.2011.03.774 · Cited by 391
Self-citationCosman, F., Eriksen, E. F., Recknor, C., Miller, P. D., Guañabens, N., Kasperk, C., Papanastasiou, P., Readie, A., Rao, H., Gasser, J. A., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.238 · Cited by 359
Metadata
- Authors
- RUSSELL, R. G. G., XIA, Z., DUNFORD, J. E., OPPERMANN, U., KWAASI, A., HULLEY, P. A., KAVANAGH, K. L., TRIFFITT, J. T., LUNDY, M. W., PHIPPS, R. J., BARNETT, B. L., COXON, F. P., ROGERS, M. J., WATTS, N. B., & EBETINO, F. H.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2007-11
- Volume
- 1117
- Issue
- 1
- Pages
- 209-257
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2029620076
- Cited by
- 391
- References
- 158
- FWCI
- 14.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.